New hope for AML patients: targeted drug may outperform standard care after transplant
NCT ID NCT07463651
First seen Mar 17, 2026 · Last updated May 16, 2026 · Updated 10 times
Summary
This study tests whether the drug gilteritinib works better than sorafenib at keeping leukemia from coming back in people with a specific genetic mutation (FLT3-ITD) after a stem cell transplant. About 594 participants will be randomly assigned to take one of the two drugs for up to 2 years. The goal is to see which drug better prevents cancer relapse and improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200025, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
the First Affiliated Hosptital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.